![\"\"](\"https:\/\/yogaesoteric.net\/wp-content\/uploads\/2026\/09\/billi1-e1789760229427.webp\")
<\/p>\n<\/p>\n
When Lucy Ackman, the 26-year-old daughter of billionaire hedge fund manager Bill Ackman, lost her sight after a brain haemorrhage, her family could mobilize a medical network unavailable to almost anyone else. Her doctors at Mount Sinai obtained emergency FDA authorization for the first mitochondrial transplant ever attempted in human eyes. For several weeks, the experimental procedure restored a limited ability to perceive light.<\/p>\n Following the incident, Ackman announced plans to create a research institute focused on brain science, neural restoration and longevity. His move comes amid a broader race among the US tech elite: Sam Altman is backing Retro Biosciences, Jeff Bezos was reported as an early backer of Altos Labs, and Peter Thiel supports multiple ventures aimed at extending human life and rewriting the rules of aging.<\/p>\n From Economic Inequality to Biological Divide<\/strong><\/p>\n These initiatives converge around a single premise \u2013 human biology has become the newest frontier of technological competition. But with scientific breakthroughs come uncomfortable questions of access. If such innovations remain largely in the hands of those who finance them, the gap between rich and poor may eventually cease to be purely economic and could harden into a biological divide.<\/p>\n The upper tier of the new biomedical race is forming around rapidly advancing fields: personalized medicine, genetic analysis, cell-based therapies, and longevity research. These approaches are already being used in scientific programs and private projects, where treatment is increasingly built not around the average patient but around personal biological characteristics.<\/p>\n The NIH\u2019s All of Us Research Program<\/em>, for example, is building one of the largest biomedical databases in the United States, combining genomic information, electronic health records, and other participant data to advance personalized medicine. Some of the most expensive and experimental projects, from cellular rejuvenation to life-extension technologies, are today being developed with backing from major private investors.<\/p>\n Some of the wealthiest figures in the American tech elite have already entered this race. Jeff Bezos, the founder of Amazon, was reported as an early backer of Altos Labs, a company studying cellular rejuvenation and the repair of damaged cells. Sam Altman, the head of OpenAI, supports Retro Biosciences, which is developing therapies targeting aging and age-related diseases and aims to extend the human health span.<\/p>\n For most people, medicine remains something else: mass diagnostics, standard treatment protocols, and the long wait for new developments to trickle down to ordinary patients. Even now, research shows that the distribution of resources in biomedicine is not entirely even. Funding concentrates around the wealthiest research centres and the largest industry players.<\/p>\n How Silicon Valley Gained Power Over the Future of Biology. Artificial Intelligence as a Tool<\/strong><\/p>\n The largest technology companies now sit at the centre of the modern digital economy, controlling platforms, infrastructure and AI systems that increasingly shape how information is processed, analysed and produced.<\/p>\n Those resources matter in modern biomedicine. Research increasingly depends on processing huge volumes of genetic data, modelling complex biological systems and running expensive computational workloads. The US National Academies of Sciences, Engineering, and Medicine has noted that progress in AI-driven biology depends heavily on data quality, computing capacity and the ability to combine large datasets.<\/p>\n OpenAI has already moved into this area with specialized tools for biological research and drug discovery. GPT-Rosalind was developed for work involving biological research, including genes, proteins and scientific data, and OpenAI says it can accelerate parts of the research process and drug discovery.<\/p>\n Access to the model itself reflects the same divide emerging across biotechnology: GPT-Rosalind is available only to a limited group of qualified US Enterprise customers through OpenAI\u2019s trusted access program, while standard models and research tools are available more broadly. The result is a tiered system where access to advanced biological AI infrastructure depends not only on scientific need, but also on institutional position.<\/p>\n The concentration of these capabilities shows who holds leverage over future medical research. Technology companies are no longer limited to controlling digital platforms or access to information; they are increasingly involved in building the tools scientists may rely on to design the next generation of therapies. That gives private technology companies influence over the direction of research, including which capabilities are developed first and who gains access to them.<\/p>\n Sam Altman: AI and the Privatization of Biological Discovery<\/strong><\/p>\n Artificial intelligence is becoming part of biological science. Once mainly used for information retrieval, office automation and digital content creation, AI is now used to analyse genetic data, study proteins, search for drug compounds and model complex processes inside cells.<\/p>\n Sam Altman, the head of OpenAI, sits at the intersection of artificial intelligence and biotechnology. Through AI development and investments in life sciences, he has become part of a system where control over data, algorithms and biological research is increasingly concentrated among a small group of technology leaders.<\/p>\n He backs Retro Biosciences, a company focused on cellular reprogramming and research into extending the human health span. Altman invested $180 million in Retro Biosciences, making it one of the clearest examples of billionaire-backed attempts to redesign the biology of aging. The company says its goal is to add ten years of healthy life through cell restoration technologies \u2013 a promise that, if fulfilled, would become one of the most valuable achievements in modern medicine.<\/p>\n Altman\u2019s role in this field goes beyond funding certain biotechnology projects. His position at OpenAI connects AI infrastructure with life sciences, where artificial intelligence systems are increasingly adapted for scientific research. The combination of advanced AI models and biotechnology creates a new research model, bringing computing power and biological expertise together to accelerate research processes that traditionally require extensive laboratory and computational work.<\/p>\n Peter Thiel: The Philosophy of the Enhanced Human<\/strong><\/p>\n The development of biotechnology is changing not only how diseases are treated, but also how the limits of human life are understood. For a growing group of Silicon Valley investors, aging is no longer viewed as a natural process. It has become a field for experimentation, where science and capital work in tandem.<\/p>\n Peter Thiel, co-founder of PayPal and one of Silicon Valley\u2019s most influential investors, has been one of the most outspoken supporters of longevity research. In 2006, he pledged $3.5 million to the Methuselah Foundation to support SENS research (Strategies for Engineered Negligible Senescence, a regenerative medicine approach designed to repair the cellular and molecular damage that builds up in the body over time.). He was also an early investor in Unity Biotechnology, which pursued drugs targeting senescent cells. Together, those bets reflect his view of aging and human biology as engineering problems.<\/p>\n This vision is pure transhumanism, an ideology that holds that technology should free humanity from biological constraints. Adherents treat aging as a disease to be defeated. The people who use their discernment, however, see something else: an attempt by a narrow group of billionaires and corporations to claim the right to define what an \u201cenhanced person\u201d should be and by what standards they should be judged, ominously altering the human race.<\/p>\n Jeff Bezos: The Business of Owning the Future of Human Longevity<\/strong><\/p>\n For most of human history, aging was treated as a biological reality medicine could manage but not fundamentally modify. Silicon Valley investors are now treating aging as a technical problem \u2013 something that can be studied, engineered and turned into a market.<\/p>\n Jeff Bezos, the founder of Amazon and one of the wealthiest people in the world, was reported as one of the early backers of Altos Labs, a biotechnology company launched with $3 billion in initial financing. The company recruited leading scientists to study cellular rejuvenation, including research into partial cellular reprogramming, in which cells retain their identity while recovering functions associated with younger cells.<\/p>\n Altos Labs marks a more commercial phase in longevity research. Billionaire-backed companies such as Altos Labs are building privately funded research organizations, hiring prominent scientists and directing capital toward technologies aimed to reshape human health.<\/p>\n If cellular rejuvenation and life-extension technologies become effective medical tools, access will depend heavily on who controls the companies, patents and infrastructure behind them. A system that already produces extreme inequality in wealth could eventually produce inequality in lifespan and biological advantage.<\/p>\n Altos Labs is a biotech company, but its scale and private financing also reflect the growing influence of private capital over aging research. The stakes are unusually high because the research could lead to treatments that restore cellular health and address diseases associated with aging. In that market, the first people to benefit are likely to be those closest to the money, the companies and the research.<\/p>\n Who Gets Access?<\/strong><\/p>\n Medical inequality already determines who gets the best care, how quickly they get it and which specialists they can reach. The arrival of gene therapies, cellular treatments and longevity technologies could make that divide far more consequential. These technologies are complex, expensive and, at least in their early stages, likely to remain concentrated in specialized medical centres.<\/p>\n That price barrier is already visible in gene therapy. Lenmeldy, a one-time treatment for children with a rare inherited neurological disease, was priced at $4.25 million when it entered the US market. Hemgenix, a one-time gene therapy for adults with haemophilia B, was launched with a list price of $3.5 million. These examples show that the question of who can afford advanced biological treatments is no longer hypothetical.<\/p>\n For the wealthy, scarcity creates fewer barriers. Money can pay for consultations with leading specialists, travel to major medical centres and the time required to pursue treatments unavailable through ordinary channels. Bill Ackman\u2019s daughter did not bypass the FDA. Her doctors obtained emergency authorization for an experimental mitochondrial transplantation, but the family had access to Mount Sinai, leading physicians and a network of well-connected contacts around the world. That placed them unusually close to experimental medicine when conventional options were limited.<\/p>\n Even if we assume that some of the new longevity treatments are to be safe and not involve transhumanism, those would be reserved for the rich. High prices, limited supply, specialized facilities and restricted early access are enough to set the rich vs poor divide.<\/p>\n Source: Geopolitics Prime<\/em><\/p>\n \u00a0<\/em><\/p>\n yogaesoteric <\/p>\n","protected":false},"excerpt":{"rendered":" When Lucy Ackman, the 26-year-old daughter of billionaire hedge fund manager Bill Ackman, lost her sight after a brain haemorrhage, her family could mobilize a medical network unavailable to almost anyone else. Her doctors at Mount Sinai obtained emergency FDA authorization for the first mitochondrial transplant ever attempted in human eyes. For several weeks, the […]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[382],"tags":[1516],"class_list":["post-243748","post","type-post","status-publish","format-standard","hentry","category-opinions-1602-en","tag-article_of_the_week"],"_links":{"self":[{"href":"https:\/\/yogaesoteric.net\/en\/wp-json\/wp\/v2\/posts\/243748","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/yogaesoteric.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/yogaesoteric.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/yogaesoteric.net\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/yogaesoteric.net\/en\/wp-json\/wp\/v2\/comments?post=243748"}],"version-history":[{"count":1,"href":"https:\/\/yogaesoteric.net\/en\/wp-json\/wp\/v2\/posts\/243748\/revisions"}],"predecessor-version":[{"id":243798,"href":"https:\/\/yogaesoteric.net\/en\/wp-json\/wp\/v2\/posts\/243748\/revisions\/243798"}],"wp:attachment":[{"href":"https:\/\/yogaesoteric.net\/en\/wp-json\/wp\/v2\/media?parent=243748"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/yogaesoteric.net\/en\/wp-json\/wp\/v2\/categories?post=243748"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/yogaesoteric.net\/en\/wp-json\/wp\/v2\/tags?post=243748"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"\"](\"https:\/\/yogaesoteric.net\/wp-content\/uploads\/2026\/09\/billi2.jpg\")
![\"\"](\"https:\/\/yogaesoteric.net\/wp-content\/uploads\/2026\/09\/billi3-e1789760298389.jpg\")
<\/p>\n![\"\"](\"https:\/\/yogaesoteric.net\/wp-content\/uploads\/2026\/09\/billi4-e1789760366160.jpg\")
<\/p>\n![\"\"](\"https:\/\/yogaesoteric.net\/wp-content\/uploads\/2026\/09\/billi5-e1789760400882.jpg\")
![\"\"](\"https:\/\/yogaesoteric.net\/wp-content\/uploads\/2026\/09\/billi6-e1789760435161.jpg\")
![\"\"](\"https:\/\/yogaesoteric.net\/wp-content\/uploads\/2026\/09\/billi7.jpg\")
![\"\"](\"https:\/\/yogaesoteric.net\/wp-content\/uploads\/2026\/09\/billi8.jpg\")
![\"\"](\"https:\/\/yogaesoteric.net\/wp-content\/uploads\/2026\/09\/billi9.webp\")
![\"\"](\"https:\/\/yogaesoteric.net\/wp-content\/uploads\/2026\/09\/billi10.webp\")
![\"\"](\"https:\/\/yogaesoteric.net\/wp-content\/uploads\/2026\/09\/billi11-e1789760572138.webp\")
\nSeptember 18, 2026<\/strong><\/p>\n